Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France

• DOI: 10.1007/s00417-017-3685-y
• Publication Date: 2017-05-10T09:32:48Z
• Authors: Gérard Mimoun; Jean-Marc Ebran; Typhaine Grenet; Alain Donati; Salomon-Yves Cohen; Anne Ponthieux
• Keywords: Pseudoxanthoma Elasticum; Angioid streaks

To evaluate the long-term effectiveness and safety of ranibizumab 0.5 mg in patients with choroidal neovascularization (CNV) secondary to pseudoxanthoma elasticum (PXE) a real-world setting. A descriptive, observational, multicenter study retrospective prospective cohort was conducted France that included who had received at least one injection during period October 2011 2014, for CNV PXE. Eligible were identified by review medical records or routine consultations. The main objectives describe patient characteristics, assess changes best-corrected visual acuity [VA, Early Treatment Diabetic Retinopathy Study (ETDRS) letters] over time, number reasons treatment overall safety. Of 72 enrolled (98 eyes) from 23 centers, 39 (54.2%) male mean [±standard deviation (SD)] age 59.6 (±8.3) years. VA 64.6 letters first injection, which maintained 1-year follow-up (64.7 letters). Thereafter, stable until 4-year follow-up. At 4 years, proportion eyes gain ≥15 3/19 (15.8%) (change between −15 +15 letters) 10/19 (52.6%). Mean (±SD) annual injections 4.1 (±4.0), lower second versus year. most common reason progression neovascular activity (42.9%). No deaths new findings reported. In PXE, resulted years limited injections. Safety consistent established profile ranibizumab.